GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency
You may also be interested in...
Experts Support Statin, Triptan, Sleep Aid Switches In New Paradigm
The American Society of Health-System Pharmacists has opposed allowing OTC sales of statins, but would support a switch made with conditions of safe use required. A Philadelphia College of Pharmacy professor argues that patients are better served by obtaining pharmaceuticals from health care professionals than using “un-standardized” dietary supplements
Experts Support Statin, Triptan, Sleep Aid Switches In New Paradigm
The American Society of Health-System Pharmacists has opposed allowing OTC sales of statins, but would support a switch made with conditions of safe use required. A Philadelphia College of Pharmacy professor argues that patients are better served by obtaining pharmaceuticals from health care professionals than using “un-standardized” dietary supplements
Rx-to-OTC Switch Interest Explodes Following Deal Activity - Experts
Pharmaceutical firms are developing and reshaping their Rx-to-OTC switch strategies to remain competitive in an evolving industry where recent mergers and acquisitions underscore the importance of an OTC presence and switch platform